Corporate Vice President, General Manager of Gu’an Toxicology Facility

Chinese Academy of Toxicology Certified Toxicologist. PhD of toxicology. Member of the American Society of Toxicology, Member of the Professional Committee of Drug Toxicology and Safety Evaluation of the Chinese Society of Toxicology, CDE New Drug Review Expert.

Corporate Vice President and Director of Pharmacology and Efficacy Division

PhD in pharmacology from the Chinese Academy of Sciences.  Served as the study director of pharmacology and toxicology topic of Joinn new medicine, the head of the pharmacology department and the senior regulatory consultant prior to join SAFE.

General Manager of Sichuan Facility

Primate and Neurotoxicology Specialist, Doctor of neurotoxicology. Participated in the Ministry of Science and Technology "863" program related to animal models of primate diseases, the National Natural Science Foundation of China, etc.

Corporate Vice President and CMO

Received Master Degree from Northeast Agricultural University of China. Worked at WuXi AppTec as Sales Director prior to Join SAFE.  Also served as Manager of Marketing Department of Joinn New Drug Research Center and Director of Quality Assurance Department of Suzhou Joinn New Drug Research Center.

Senior Scientific Advisor, GxP Compliance

Dr. Alan Liss is a Ph.D. in Microbiology with over 25 years of successful experience focusing on development and manufacturing of biologics and vaccines. He designed and executed effective US and global manufacturing strategies to support the improvement of quality and compliance for biopharmaceutical companies. He also created and led teams acting as the foundation of the support systems of US government programs designed to advance the development and manufacturing of medical countermeasures (MCM). During his career, he served as Subject Matter Expert for merger and acquisition activities in US and Europe valued at hundreds of millions of dollars (US). He also evaluated manufacturing suitability and compliance profiles for global biologics manufacturers.

DABT, Inhalation and toxicology Specialist

In over 20 years of R&D, Dr. Reed has been exposed to hundreds of small molecule, biologic, oligonucleotide, and device mitigation strategies designed to positively impact respiratory, cardiovascular, cancer, metabolic, infectious, and rare-neglected disease states, etc. He has contributed to 10-plus successful clinical programs or regulatory registrations of drugs and other products and has authored 120+ publications, abstract presentations, and regulatory-based final reports. Dr. Reed has served on two international committees and published two position papers that facilitated the reversal of regulatory (FDA) opinions related to pathologic adversity of inhaled pharmaceuticals (e.g., the “macrophage response”) and has twice been invited to participate in FDA-wide educational seminar panels on the inhaled route of delivery.

DVM, DAVCP, Consultant, Veterinary Anatomical Pathology

Dr. G. David Young has over thirty-plus years’ experience in biomedical research in government (US Army), contract research organizations and the pharmaceutical industry.  Research areas include oncology and biomarker development, infectious disease research and toxicological pathology.  

DVM, DACVP, Consultant, Veterinarian Clinical Pathology

Dr. Pearson has over 27 years of experience in the field of toxicologic clinical pathology during which time she authored thousands of professional clinical pathology reports for preclinical GLP toxicology studies.